GLPwatch
Papers (10372)
Page 20 of 173, ranked by citation count.
- Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction.
- Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program.
- Post hoc analysis of the Exenatide-PD trial-Factors that predict response.
- Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.
- Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
- Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.
- Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction.
- Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.
- The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics.
- Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.
- Liraglutide inhibits autophagy and apoptosis induced by high glucose through GLP-1R in renal tubular epithelial cells.
- Semaglutide Use Prior to Total Hip Arthroplasty Results in Fewer Postoperative Prosthetic Joint Infections and Readmissions.
- GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
- Injectable hydrogel for sustained protein release by salt-induced association of hyaluronic acid nanogel.
- LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.
- Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review.
- Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
- COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES.
- Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.
- Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function.
- Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review).
- Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States.
- Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.
- Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity.
- Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease.
- Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.
- Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial.
- Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
- Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment.
- Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation.
- Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study.
- The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis.
- Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.
- Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
- Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.
- Dipeptidyl peptidase-4 inhibitor improved exercise capacity and mitochondrial biogenesis in mice with heart failure via activation of glucagon-like peptide-1 receptor signalling.
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
- An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy.
- Diabesity: therapeutic options.
- Stable Incretin Mimetics Counter Rapid Deterioration of Bone Quality in Type 1 Diabetes Mellitus.
- Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome.
- Expression of the glucagon-like peptide-1 receptor and its role in regulating autophagy in endometrial cancer.
- The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery-a Retrospective Analysis.
- Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.
- Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors.
- Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
- Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series.
- Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study.
- Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder.
- Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
- Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis.
- Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents.
- Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss.
- Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study.
- Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
- GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review.
- Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.